• Before neoadjuvant chemotherapy, pancreatic ductal adenocarcinoma was confirmed by pathology;

• According to the guidelines, neoadjuvant chemotherapy should be performed before surgery, including patients with resectable pancreatic cancer (RPC) with high risk factors (biologically borderline resectable), anatomically borderline resectable pancreatic cancer (BRPC) with good physical condition;

• Receive at least 2 cycles of neoadjuvant chemotherapy before radical surgery；

• After neoadjuvant chemotherapy, the patient can be further treated by laparoscopic or open surgery;

• No obvious surgical contraindications, suitable for minimally invasive surgery;

• ECOG score of preoperative physical condition was 0-1;

• No history of preoperative pancreatitis;

• Preoperative PET-CT or other imaging examination did not show distant metastasis;

• The expected postoperative survival time was more than 3 months;

• Be able to comply with research protocol, follow-up plan and other protocol requirements;

• Voluntary participation and signed informed consent.